Vai al contenuto principale
Logo Università
Logo di Dipartimento di Oncologia

Dipartimento di Oncologia

Dipartimento di Oncologia

Logo di Dipartimento di Oncologia

Sabrina Arena

Professore/Professoressa associato/a

Contatti

Presso

  • Department of Oncology
  • Dipartimento di Oncologia
  • Artificial Intelligence for Biomedicine and Healthcare
  • Corso di laurea in Igiene Dentale
  • Corso di Laurea in Tecniche di Laboratorio Biomedico - Torino
  • Corso di Laurea Magistrale in Biotecnologie Mediche - Classe LM-9
  • Molecular Medicine PhD Program

Curriculum vitae

  • Curriculum Vitae (0.1 MB)

    • Prodotti della ricerca

    Tutti i miei prodotti della ricerca

    Prodotti della ricerca selezionati

    1. Durinikova E, Reilly NM, Buzo K, Mariella E, Chilà R, Lorenzato A, Dias JML, Grasso G, Pisati F, Lamba S, Corti G, Degasperi A, Cancelliere C, Mauri G, Andrei P, Linnebacher M, Marsoni S, Siena S, Sartore Bianchi A, Nik-Zainal S, Di Nicolantonio F, Bardelli* A and Arena* S. Targeting the DNA Damage Response pathways and Replication Stress in Colorectal Cancer. In press. *coLast and coCorresponding authors
    2. Amatu A, Mauri G, Tosi F, Bencardino K, Bonazzina E, Gori V, Ruggieri L, Arena S, Bardelli A, Marsoni S, Siena S, and Sartore-Bianchi A. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. Cancers 2022, 14(5), 1197
    3. Mauri G*, Durinikova E*, Amatu A, Tosi F, Cassingena A, Buzo F, Rizzetto F, Arcella A, Aquilano MC, Marsoni S, Bonoldi E, Salvatore Siena, Alberto Bardelli, Andrea Sartore-Bianchi# and Arena S#. Empowering clinical decision-making in oligometastatic colorectal cancer: the potential role of drug screening of patient-derived organoids. JCO Precis Oncol. 2021 Jul; 5: PO.21.00143 *co-First authors; #co-Last and corresponding author
    4. Durinikova E, Buzo K and Arena S,*. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges. J Exp Clin Cancer Res 40, 185 (2021). https://doi.org/10.1186/s13046-021-01981-z *Last and Corresponding author
    5. Picco G, Cattaneo C, Van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira S F, Sánchez Rodríguez I, Cancelliere C, Banerjee R, Schipper L, Oddo D, Dijkstra K, Cinatl J, Michaelis M, Yang F, Cell Model Network UK Group, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Arena S, Voest* E, Bardelli* A, and Garnett* MJ. Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. Cancer Discov. 2021 Apr 9:candisc.1508.2020. (*co-Last authors)
    6. Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev. 2020 Dec;91:102112. doi: 10.1016/j.ctrv.2020.102112. Epub 2020 Oct 9. PMID: 33091698.
    7. Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discov. 2021 Jan;11(1):126-141. doi: 10.1158/2159-8290.CD-20-0571. Epub 2020 Oct 1. PMID: 33004339; PMCID: PMC8012405.
    8. Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discov. 2020 Aug;10(8):1129-1139. doi: 10.1158/2159-8290.CD-20-0187.
    9. Mauri G, Arena S#, Siena S, Bardelli A, Sartore-Bianchi A. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol. 2020 Sep;31(9):1135-1147. doi: 10.1016/j.annonc.2020.05.027. # Co-First and co-Corresponding author
    10. Lorenzato A, Magrì A, Matafora V, Audrito V, Arcella P, Lazzari L, Montone M, Lamba S, Deaglio S, Siena S, Bertotti A, Trusolino L, Bachi A, Di Nicolantonio F, Bardelli A and Arena S#. Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. Cancers (Basel). 2020 Mar 14;12(3):685. doi: 10.3390/cancers12030685. PMID: 32183295; PMCID: PMC7140052. #Last and Corresponding author
    11. Magrì A, Germano G, Lorenzato A, Lamba S, Chilà R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, Abrignani S, D’Incalci M, Zucchetti M, Di Nicolantonio F and Bardelli A. High-dose vitamin C enhances cancer immunotherapy. Sci Transl Med. 2020 Feb 26;12(532):eaay8707. doi: 10.1126/scitranslmed.aay8707. PMID: 32102933.
    12. Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, Pagani M, Cancelliere C, Negrino C, Isella I, Bartolini A, Cassingena A, Amatu A, Mauri G, Sartore-Bianchi A, Mittica G, Medico E, Marsoni S, Linnebacher M, Abrignani S, Siena S, Di Nicolantonio F, and Bardelli A. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clin Cancer Res. 2020 Mar 15;26(6):1372-1384. doi: 10.1158/1078-0432.CCR-19-2409. Epub 2019 Dec 12. PMID: 31831554.
    13. Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, Bartolini A, Amodio V, Magrì A, Novara L, Sarotto I, Nagel ZD, Piett CG, Amatu A, Sartore-Bianchi A, Siena S, Bertotti A, Trusolino L, Corigliano M, Gherardi M, Lagomarsino MC, Di Nicolantonio F, Bardelli A. Adaptive mutability of colorectal cancers in response to targeted therapies. Science. 2019 Dec 20;366(6472):1473-1480. doi: 10.1126/science.aav4474. Epub 2019 Nov 7. PMID: 31699882.
    14. Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, Durinikova E, Zanella ER, Novara L, Barbosa F, Cassingena A, Cancelliere C, Medico E, Sartore-Bianchi A, Siena S, Garnett MJ, Bertotti A, Trusolino L, Di Nicolantonio F, Linnebacher M, Bardelli A and Arena S#. Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer. Clin Cancer Res. 2019 Oct 15;25(20):6243-6259. doi: 10.1158/1078-0432.CCR-18-3440. Epub 2019 Aug 2. PMID: 31375513. #co-Last and Corresponding author
    15. Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, Di Nicolantonio F, Bardelli A. Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nat Commun. 2018 Jun 12;9(1):2287
    16. Arena S, Salati M, Sorgentoni G, Barbisan F, Orciani M. Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer. Clin Transl Oncol. 2018 Dec;20(12):1582-1591. doi: 10.1007/s12094-018-1894-4. Epub 2018 May 23. PMID: 29796998.
    17. Ali M, Kaltenbrun E, Anderson GR, Stephens S.J, Arena S, Bardelli A, Counter C.M, Wood K.C. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance (2017) Nature Communications 8 art. no. 15617
    18. Van Emburgh B.O*, Arena S*, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665. PMID: 27929064; PMCID: PMC5155160. * co-First authors
    19. Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer. Cancer Res. 2016 Jun 16
    20. Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. Clin Cancer Res. 2016 Feb 17. 
    21. Arena S#, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016 Feb 3;8(324):324ra14. doi:10.1126/scitranslmed.aad5640. PMID: 26843189. # First and co-Corresponding author
    22. Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sanchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res. 2015 May 1;21(9):2157-66. doi: 10.1158/1078-0432.CCR-14-2821. Epub 2015 Jan 26. PMID: 25623215.
    23. Lu S, Török HP, Gallmeier E, Kolligs FT, Rizzani A, Arena S, Göke B, Gerbes AL, De Toni EN. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1. Oncotarget. 2015 Jun 10.
    24. Misale* S, Arena* S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947. PMID: 24553387. * co-First authors
    25. Olivero M, Dettori D, Arena S, Zecchin D,Lantelme E, Di Renzo MF. The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase. Oncotarget. 2014 Aug 15;5(15):5992-6002
    26. Crowley EH, Arena S, Lamba S, Di Nicolantonio F,Bardelli A. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Hum Mutat. 2014 Feb;35(2):208-14
    27. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Mol Cancer Ther. 2013 Dec;12(12):2950-6
    28. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res. 2013 May 1;19(9):2381-92.
    29. Zecchin D, Arena S, Martini M, Sassi F, Pisacane A, Di Nicolantonio F, Bardelli A. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. Hum Mutat. 2013 Feb;34(2):330-7.
    30. Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, Belvin M, Friedman LS. Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or promoted by Blocking the Pathway at Divergent Nodes. PLoS One. 2012;7(5):e36402
    31. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac, D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. PNAS 2011 Oct 25;108(43):17773-8.
    32. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba M, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010 Oct 27;304(16):1812-20
    33. Di Nicolantonio F*, Arena* S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S and Bardelli A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010 Aug;120(8):2858-66. doi: 10.1172/JCI37539. Epub 2010 Jul 26. PMID: 20664172; PMCID: PMC2912177. * co-First authors
    34. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S. Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol. 2010 Apr 11.
    35. Di Nicolantonio F*, Arena * S, Gallicchio M and Bardelli A. Isogenic Mutant Human Cells: A New Tool for Personalized Cancer Medicine. Cell Cycle. 2010 Jan 1;9(1):20-1. Epub 2010 Jan 29. * co-First authors
    36. Flonta SE, Arena S, Pisacane A, Michieli P, Bardelli A. Expression and functional regulation of myoglobin in epithelial cancers. Am J Pathol. 2009 Jul;175(1):201-6
    37. Di Nicolantonio F*, Arena* S, Gallicchio M*, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20864-9. doi: 10.1073/pnas.0808757105. Epub 2008 Dec 23. PMID: 19106301; PMCID: PMC2634925. * co-First authors.
    38. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008 Dec 10;26(35):5705-12
    39. Arena S, Bardelli A. Understanding how kinase-targeted therapies work. Cell Cycle. 2008 Jun;7(11):1560-3.
    40. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti M and Bardelli A. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat. 2008 Feb;29(2):284-8.
    41. Saletta F, Matullo G, Manuguerra M, Arena S, Bardelli A and Vineis P. Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. Cancer Res. 2007 Aug 1;67(15):7088-94.
    42. Arena S, Isella C, Martini M, De Marco A, Medico E and Bardelli A. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res. 2007 Sep 15;67(18):8468-76. doi: 10.1158/0008-5472.CAN-07-1126. PMID: 17875685
    43. Arena S, Pisacane A, Mazzone M, Comoglio PM and Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11412-7. doi: 10.1073/pnas.0703205104. Epub 2007 Jun 26. PMID: 17595299; PMCID: PMC2040912.
    44. Karakas B, Weeraratna A, Abukhdeir A, Blair BG, Konishi H, Arena S, Becker K, Wood W, Argani P, De Marzo AM, Bachman KE, Park BH. Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells. Oncogene. 2006 Sep 7;25(40):5561-9
    45. Arena S, Benvenuti S, Bardelli A. Genetic analysis of the kinome and phosphatome in cancer. Cell Mol Life Sci. 2005 Sep;62(18):2092-9
    46. Benvenuti S, Arena S, Bardelli A. Identification of cancer genes by mutational profiling of tumor genomes. FEBS Lett. 2005 Mar 21;579(8):1884-90.
    47. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH. p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther. 2004 Feb;3(2):221-5.

     

    Insegnamenti

    Titolare del corso di "Genetica Oncologica" presso la scuola di specializzazione in Genetica Medica

    Temi di ricerca

    upload_Banner-ARENA-Lorenzato5.png

    Sabrina Arena, Ph.D.     

    Associate Professor University of Torino, School of Medicine                                                              

    Translational Cancer Genetics Laboratory at IRCCS Candiolo

    E-mail: sabrina.arena@unito.it
    Phone. +39.011.9933223
    Fax. +39.011.9933225

    Publications

    Research topic:

    Overcoming resistance to therapies exploiting tumor DNA repair and metabolic vulnerabilities

    Background:

    Therapeutic resistance, either as an intrinsic (primary) feature or as an acquired (secondary) trait upon the use of targeted or chemotherapeutic agents, represents the major cause of treatment failure in cancer patients. The identification of culprits of resistance or, on the other side, of determinants of sensitivity to therapy denotes an unmet medical need for the design of novel strategies to overcome resistance and to prolong disease control in cancer patients. Thanks to the increased knowledge in tumor biology, genomic profiling, that has driven in the last two decades the primary precision medicine strategy to guide patient care, should be now coupled to more complex non-genetic profiling to extend therapeutic benefit also to that large part of patients that are not responding to common actionable targets. Tumors of colorectal, prostate and ovarian origin are among the top five solid malignancies affecting cancer patients worldwide (Siegel et al, cancer Statistics 2022). Although these tissues are heterogeneous and different for embryonic origins and functions, common mechanisms of survival might be exploited and targeted to lethally impair tumor growth and progression.

    Research achievements:

    Previous work has led to the discovery of genetic mechanisms of acquired resistance to anti-EGFR therapy in colorectal cancer (CRC), in particular to the identification of mutations in the EGFR pathway (Misale*, Arena* et al. Sci Transl Med 2014) and in the EGFR extracellular domain (ECD) (Arena et al, Clin Cancer Res 2015; Arena et al. Sci Transl Med 2016). By modelling evolution of resistance in vitro upon drug pressure, we have also shown that a clinical correlation can occur between the genetic profile of the patients and their clinical outcome, thus highlighting the profound implications of tumor heterogeneity on therapy (Van Emburgh*, Arena* et al. Nature Comm 2016). While most common therapeutic approaches might adapt to the 'resistant genetic profile' of the patient (Arena et al. Sci Trasl Med 2016), we have recently devised novel strategies that take advantage of intrinsic or acquired susceptibilities independent  from the EGFR axis and standing from metabolic vulnerabilities (Lorenzato, and Arena, Cancers 2020) to DNA repair pathway dependencies (Arena et al, Clin Cancer Res 2020; Durinikova et al, Clin Cancer Res 2022). These liabilities might embody putative and effective druggable targets for cancer treatment. In addition, establishment of preclinical platforms of patient-derived models that faithfully mirror the molecular and heterogeneous clinical-pathological features of the disease (Lazzari et al, Clin Cancer Res 2019; Durinikova et al, J Exp Clin Cancer Res. 2021, Mauri*, Durinikova* et al, JCO Precis Oncol. 2021) has shown successful translational application of these therapeutic strategies to treat cancer patients.

    Conclusions and perspectives:

    The laboratory of prof. Arena is currently focused on the design of novel therapeutic strategies to overcome heterogeneous resistance in cancers of colorectal, prostate and ovarian origin. This could be achieved by exploiting the combination of common targeted or chemotherapeutic agents with the unconventional and concomitant targeting of collateral cell vulnerabilities. Development of cancer therapies based on synthetic lethal targeting of the DNA damage response (DDR) and metabolic pathways might provide an opportunity for the design of novel drug combinations to elicit synergistic activity with tolerable toxicities and foster the long-term response to therapies. Translational application is provided by testing efficacy in patient-derived preclinical models (cell lines and organoids, PDXs) that faithfully recapitulate the clinical settings of these tumors.

    Staff

    Kristi BuzoKristi Buzo, Dr
    PhD student
    E-mail: Kristi.buzo@ircc.it
    Phone. +39.011.9933223

    Clelia NisticòClelia Nisticò, Dr
    Post Doc (postdoctoral fellowship)
    E-mail: clelia.nisticò@ircc.it
    Phone. +39.011.9933223

    Laura BizzozeroLaura Bizzozero, Dr
    Research assistant
    E-mail: laura.bizzozero@ircc.it
    Phone. +39.011.9933223

    Marilena LentiniMarilena Lentini
    Undergraduate Student (Medical Biotechnology)
    Email: marilena.lentini@edu.unito.it 
    Phone. +39.011.9933223

    Emanuela LombardoEmanuela Lombardo
    Undergraduate Student (Laboratory Technician)
    E-mail: 303564@edu.unito.it
    Phone. +39.011.9933223

    Giada De LazzariGiada De Lazzari
    Post Doc (postdoctoral fellowship)
    E-mail: giada.delazzari@ircc.it
    Phone. +39.011.9933223

    Alena OpattovaAlena Opattova
    Post Doc (postdoctoral fellowship)
    E-mail: alena.opattova@ircc.it
    Phone. +39.011.9933223

    Former Members

    upload_ericadurinikova.pngErika Durinikova, PhD

    Postdoctoral Fellow

    Attività in agenda

    Consulta la mia agenda

    Organi

    Ricevimento studenti

    Previo appuntamento telefonico o via e-mail (sabrina.arena@unito.it).

    Ultimo aggiornamento: 16/03/2023 12:42
    Location: https://www.oncology.unito.it/robots.html
    Non cliccare qui!